Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients

Abstract

Purpose This research was intended to explore the effects of new-generation basal insulin (degludec U100 And glargine U300) versus long-acting basal insulin (glargine U100, detemir) on the incidence of diabetic ketoacidosis episodes and diabetes treatment measures. Patients and methods This is a cross-sectional, retrospective medical record analysis. The study population included adults with type 1 diabetes mellitus (DM) who were on the hospital records in 2020. Data were collected from 221 eligible participants through review of electronic medical records. Each record was scanned for basal insulin type, total daily insulin dose, diabetic ketoacidosis (DKA) occurrences, and glycated hemoglobin A1C (HbA1c) levels. Data were collected from 6 months before to 6 months after the initiation of ultra-long-acting insulin. Statistical analysis was conducted using R version 3.5.2. The normality of distribution for each independent variable was verified using Shapiro–Wilk tests. The independent paired t -test was used to compare insulin therapy measures between the two insulin regimens. The main outcome measures were the incidence of DKA episodes and clinical outcomes associated with diabetes. Results The HbA1c did not change significantly before and after ultra-long-acting insulin therapy was initiated (9.9 vs 9.8, respectively; P >0.05). Insulin total daily doses were significantly higher after shifting to ultra-long-acting insulin. Sub-analysis showed higher total daily insulin doses in glargine U300 users compared with degludec U100 users ( P =0.0021). However, basal insulin doses did not change after treatment with ultra-long-acting insulin. No statistically significant difference in DKA occurrences was found before and after the start of ultra-long-acting insulin treatment. Conclusion The frequency of DKA episodes was not affected by changing the treatment to ultra-long-acting insulin. Moreover, the results suggest that insulin dosage and types are not the only cause of uncontrolled diabetes. Additional efforts should be made to cover all factors affecting diabetes complication control.

The Clinical Impact of Switching Basal Insulin to Insulin Degludec in Patients With Diabetes in Saudi Arabia: A Retrospective One-Group Pretest-Posttest Design Study

“…However, data from Saudi Arabia on switching patients from long-acting insulin are scarce. A retrospective study by Alsofiani et al reported the incidence of diabetic ketoacidosis (DKA) in type 1 DM patients using insulin glargine (U300) compared to insulin degludec (U100) after six months [ 20 ]. Although the focus was to evaluate the incidence of DKA, for which there was a difference between the two groups, they reported no change in HgbA1c between the two therapies (9.9 vs 9.8, respectively; P>0.05), which suggests that there were no clinical benefits between the two agents in this population.…”

“…Although the focus was to evaluate the incidence of DKA, for which there was a difference between the two groups, they reported no change in HgbA1c between the two therapies (9.9 vs 9.8, respectively; P>0.05), which suggests that there were no clinical benefits between the two agents in this population. However, the same study reported that insulin glargine (U300) users had higher insulin dose requirements when compared to insulin degludec (U100) users [ 20 ]. A Japanese study revealed that switching to insulin degludec resulted in better glycemic control in 16 weeks with lower insulin dosing requirements [ 21 ].…”